COMPANY COMMENT
CHRIS HUGHES: Biotech investors should temper optimism over cash-strapped targets
19 January 2022 - 18:33
The biotech sector is more than 40% down from its high in February 2021, while the major pharmaceutical firms are flush with cash. That sounds like the ideal condition for deal-making. But what if biotech boards and shareholders want takeover bids at yesterday’s sky-high prices?
It was found in a 2020 study by JPMorgan Chase & Co analysts that when markets fall, a takeover target’s one-year share price high is a stubborn benchmark for pricing a deal. So it can take more than a year from a market correction until buyers and sellers align. Those dynamics may now be at work...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.